S. Dowdell

发表

Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.

N. Aiyar, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Aminomethylpiperazines as selective urotensin antagonists.

D. Behm, S. Douglas, Zining Wu, 2008, Bioorganic & medicinal chemistry letters.

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4.

Carl A. Brooks, D. Holt, W. Bao, 2017, ACS medicinal chemistry letters.

GSK1562590, a slowly dissociating urotensin‐II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo

N. Aiyar, D. Behm, S. Douglas, 2010, British journal of pharmacology.

CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.

J. Briand, C. Chung, N. Varga, 2011, Bioorganic & medicinal chemistry letters.

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.

S. Semus, D. Behm, R. Bentley, 2008, Journal of medicinal chemistry.

Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.

M. Jaye, J. Trill, R. Annan, 2009, Bioorganic & medicinal chemistry letters.

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.

S. Semus, D. Behm, R. Bentley, 2007, Journal of medicinal chemistry.

Photo-caged agonists of the nuclear receptors RARgamma and TRbeta provide unique time-dependent gene expression profiles for light-activated gene patterning.

K. O'reilly, K. Link, J. Koh, 2004, Bioorganic & medicinal chemistry.

Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.

S. Semus, M. Head, D. Behm, 2007, Journal of medicinal chemistry.

Development of potent and selective small-molecule human Urotensin-II antagonists.

N. Aiyar, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1.

R. A. Reid, D. Holt, R. Gampe, 2018, ACS medicinal chemistry letters.